Research programme: mRNA vaccines - mCureX/GC Pharma
Latest Information Update: 28 Jul 2025
At a glance
- Originator mCureX Therapeutics
- Developer GC Biopharma; mCureX Therapeutics
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory tract infections
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for research development in Respiratory-tract-infections(Prevention) in South Korea (Parenteral)
- 07 Jun 2021 mCureX Technologies and GC Pharma sign a Memorandum of Understanding (MoU) to develop mRNA vaccines for Respiratory tract infections
- 07 Jun 2021 Early research in Respiratory tract infections (Prevention) in South Korea (Parenteral)